ADIPOQ and chronic kidney disease: Similar to MAFLD, CKD patients exhibit excess FFAs and abnormal levels of adipokines (e.g., adiponectin, leptin, resistin, and omentin) in their circulation, leading to systemic insulin resistance in peripheral tissue [15].